You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 石藥集團(1093.HK)漲超5% 首創在研藥物JMT601獲美國臨牀試驗批准
格隆匯 03-30 10:20
格隆匯3月30日丨石藥集團(1093.HK)拉昇漲5.18%,報9.54港元,暫成交1.95億港元,總市值1142.3億港元。石藥集團29日公佈,附屬開發的首創在研藥物JMT601(CPO107)的新藥臨牀試驗申請(IND)已獲美國食品藥品監督管理局(FDA)批准,就晚期非霍奇金氏淋巴瘤(NHL)開展臨牀試驗。公吿稱,JMT601 (CPO107)是全球首個已進入臨牀階段的具有協同靶向結合效應的雙特異性SIRPα融合蛋白。集團亦正計劃於美國進行I期臨牀研究。該等研究的臨牀數據將引領JMT601治療非霍奇金氏淋巴瘤及其他血液惡性腫瘤的進一步開發批准。匯豐研究日前重申對公司迎來增長點的看法,在過去3-4年的研發支持下,石藥開始進入收成期,料今年有2-3款新藥獲批,明年再增4-6款新藥。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account